Defence Therapeutics Inc (DTC.CX)
0.51
+0.01
(+2.00%)
CAD |
CNSX |
Aug 25, 16:00
Defence Therapeutics Enterprise Value : 37.16M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 37.16M |
| August 24, 2026 | 36.41M |
| August 21, 2026 | 37.16M |
| August 20, 2026 | 36.03M |
| August 19, 2026 | 37.16M |
| August 18, 2026 | 36.41M |
| August 17, 2026 | 36.41M |
| August 14, 2026 | 34.14M |
| August 13, 2026 | 29.22M |
| August 12, 2026 | 28.09M |
| August 11, 2026 | 29.60M |
| August 10, 2026 | 28.85M |
| August 07, 2026 | 28.85M |
| August 06, 2026 | 29.60M |
| August 05, 2026 | 28.85M |
| August 04, 2026 | 30.74M |
| July 31, 2026 | 28.85M |
| July 30, 2026 | 28.09M |
| July 29, 2026 | 28.85M |
| July 28, 2026 | 30.36M |
| July 27, 2026 | 28.85M |
| July 24, 2026 | 26.96M |
| July 23, 2026 | 26.20M |
| July 22, 2026 | 26.96M |
| July 21, 2026 | 28.47M |
| Date | Value |
|---|---|
| July 20, 2026 | 28.47M |
| July 17, 2026 | 30.36M |
| July 16, 2026 | 31.49M |
| July 15, 2026 | 31.11M |
| July 14, 2026 | 30.36M |
| July 13, 2026 | 30.74M |
| July 10, 2026 | 33.38M |
| July 09, 2026 | 33.00M |
| July 08, 2026 | 30.36M |
| July 07, 2026 | 32.63M |
| July 06, 2026 | 29.60M |
| July 03, 2026 | 31.49M |
| July 02, 2026 | 31.49M |
| June 30, 2026 | 31.87M |
| June 29, 2026 | 31.87M |
| June 26, 2026 | 35.27M |
| June 25, 2026 | 36.41M |
| June 24, 2026 | 36.41M |
| June 23, 2026 | 40.18M |
| June 22, 2026 | 35.65M |
| June 19, 2026 | 39.43M |
| June 18, 2026 | 34.14M |
| June 17, 2026 | 36.41M |
| June 16, 2026 | 38.67M |
| June 15, 2026 | 36.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Spectral Medical, Inc. | 420.22M |
| Resverlogix Corp. | 146.30M |
| Theratechnologies, Inc. | -- |
| COSCIENS Biopharma, Inc. | 3.247M |
| Restart Life Sciences Corp. | 3.313M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.962M |
| Total Expenses (Quarterly) | 2.962M |
| EPS Diluted (Quarterly) | -0.0502 |
| Earnings Yield | -21.90% |
| Normalized Earnings Yield | -18.24 |